Ignacio F. Mata

Oct 25, 2024 | nature.com | Tae-Hwi Schwantes-An |Ignacio F. Mata |James Beck |Anna Naito |Karen S. Marder |Roy N Alcalay | +6 more

Genetic testing for Parkinson’s disease (PD) is infrequently performed due to perceptions of low utility. We investigated the personal utility in PD GENEration and how results lead to enrollment in additional research studies. Participants (n = 972) underwent genetic testing, results disclosure, genetic counseling, and completed a survey examining the perceived personal utility of their results and interest in participating in additional studies. Most participants found their genetic test results useful, including satisfying curiosity (81%), feeling good about helping the medical community (80%), and having information to share with family (77%). There were no significant differences in responses based on result type. Forty-five percent of participants expressed interest in participating in research studies; whereas 16% of participants confirmed enrollment. Our results suggest that participants find personal utility in genetic testing regardless of results. Although participants may be interested in enrolling in additional research, they may need support and resources.

Sep 29, 2024 | nature.com | Gabriela Pereira |Nayron Medeiros Soares |Paula Saffie Awad |Bruno Lopes Santos-Lobato |Alastair J. Noyce |Ignacio F. Mata

AbstractParkinson’s disease (PD) is a common neurodegenerative disease that is a growing public health challenge. Estimates of the burden of PD have focused on data from high-income countries, with lower-income countries poorly described. We reviewed and examined the prevalence of PD reported by studies in low- to upper-middle-income countries. A systematic literature search was performed in the Medline/PubMed, Embase, LILACS, and Web of Science databases.

Jul 3, 2024 | cgtlive.com | Ignacio F. Mata

This is the second part of an interview with Ignacio Mata, PhD. For the first part, click here. “I'm a big believer that there is a big chance that some of the things that have been tried in the past might actually not be completely wasteful... I think the problem that we've run into for the past maybe 10 years or so is that we are grouping patients with PD as 1 single group. We know that this is not true—biologically they're very different, even the way that they present the disease.

Jul 2, 2024 | cgtlive.com | Ignacio F. Mata

“I think the closest that we are right now to something that may slow or stop the progression are those that are targeted for people that have a genetic form of PD, where the biology is at least mostly understood and is caused in some of those cases by 1 single variant. [W]e can understand what is happening biologically and we can try to compensate what the deficit is.”Parkinson disease (PD) is a highly complex disorder that is still not well understood by medical science.

Jan 30, 2024 | newsbreak.com | Ignacio F. Mata

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy